Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry R Smith

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Vaccine|December 13, 2003
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genesM Cristina Cassetti, Sue P McElhiney, Vafa Shahabi, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2019
First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy AdultsMammen P Mammen, Danielle Armas, Frank H Hughes, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2019
The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397Anna-Maria Dietl, Matthias Misslinger, Mario M Aguiar, et al.
Human Vaccines & Immunotherapeutics|August 28, 2012
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirusJukka Hartikka, Vesselina Bozoukova, Jane Morrow, et al.
The Lancet. Infectious Diseases|January 13, 2012
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trialMohamed A Kharfan-Dabaja, Michael Boeckh, Marissa B Wilck, et al.
Human Vaccines|July 20, 2007
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challengeGretchen S Jimenez, Rodrick Planchon, Qun Wei, et al.
Human Vaccines|May 22, 2009
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adultsWendy A Keitel, John J Treanor, Hana M El Sahly, et al.
Clinical Pharmacology in Drug Development|March 24, 2020
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy SubjectsPeter L Bonate, Charles Van Sant, Kathy Cho, et al.
Human Vaccines & Immunotherapeutics|July 17, 2013
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesLarry R Smith, Walter Wodal, Brian A Crowe, et al.
The Journal of Infectious Diseases|May 1, 2008
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjectsMary K Wloch, Larry R Smith, Souphaphone Boutsaboualoy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Vaccine|December 13, 2003
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genesM Cristina Cassetti, Sue P McElhiney, Vafa Shahabi, et al.
Antimicrobial Agents and Chemotherapy|August 21, 2019
First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy AdultsMammen P Mammen, Danielle Armas, Frank H Hughes, et al.
Antimicrobial Agents and Chemotherapy|August 14, 2019
The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397Anna-Maria Dietl, Matthias Misslinger, Mario M Aguiar, et al.
Human Vaccines & Immunotherapeutics|August 28, 2012
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirusJukka Hartikka, Vesselina Bozoukova, Jane Morrow, et al.
The Lancet. Infectious Diseases|January 13, 2012
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trialMohamed A Kharfan-Dabaja, Michael Boeckh, Marissa B Wilck, et al.
Human Vaccines|July 20, 2007
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challengeGretchen S Jimenez, Rodrick Planchon, Qun Wei, et al.
Human Vaccines|May 22, 2009
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adultsWendy A Keitel, John J Treanor, Hana M El Sahly, et al.
Clinical Pharmacology in Drug Development|March 24, 2020
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy SubjectsPeter L Bonate, Charles Van Sant, Kathy Cho, et al.
Human Vaccines & Immunotherapeutics|July 17, 2013
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesLarry R Smith, Walter Wodal, Brian A Crowe, et al.
The Journal of Infectious Diseases|May 1, 2008
Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjectsMary K Wloch, Larry R Smith, Souphaphone Boutsaboualoy, et al.
Pageof 3